Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of tisagenlecleucel in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia
2015-003736-13Phase 2
- Sponsor
- Novartis
- Start
- Sep 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Primary endpoint: Overall Remission Rate (ORR).
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2015-003736-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003736-13.